| Literature DB >> 35410226 |
Shuo Wang1,2, Daksh Chauhan1, Hena Patel1, Alborz Amir-Khalili3, Isabel Ferreira da Silva3, Alireza Sojoudi3, Silke Friedrich3, Amita Singh1, Luis Landeras4, Tamari Miller1, Keith Ameyaw1, Akhil Narang5, Keigo Kawaji6, Qiang Tang2, Victor Mor-Avi1, Amit R Patel7,8.
Abstract
BACKGROUND: Theoretically, artificial intelligence can provide an accurate automatic solution to measure right ventricular (RV) ejection fraction (RVEF) from cardiovascular magnetic resonance (CMR) images, despite the complex RV geometry. However, in our recent study, commercially available deep learning (DL) algorithms for RVEF quantification performed poorly in some patients. The current study was designed to test the hypothesis that quantification of RV function could be improved in these patients by using more diverse CMR datasets in addition to domain-specific quantitative performance evaluation metrics during the cross-validation phase of DL algorithm development.Entities:
Keywords: Artificial intelligence; Deep learning; Right ventricular ejection fraction; Right ventricular function
Mesh:
Year: 2022 PMID: 35410226 PMCID: PMC8996592 DOI: 10.1186/s12968-022-00861-5
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 6.903
Summary of data (total number of cardiovascular magnetic resonance (CMR) images) used during the training and cross-validation phase of the development of the deep learning (DL) algorithms described herein
| Training datasets | Cross-validation datasets | |||||
|---|---|---|---|---|---|---|
| Datasets | UKBB | ToF | Clinical | UKBB | ToF | Clinical |
| DL1 | 67,907 | 513 | 1900 | 16,977 | 0 | 0 |
| DL2 | 67,907 | 513 | 2033 | 26,179 | 460 | 9612 |
Three datasets were used during algorithm training consisting of images from the UK Biobank (UKBB), tetralogy of Fallot (ToF), and clinical dataset consisting of various pathologies including hypertrophic cardiomyopathy, dilated cardiomyopathy, pulmonary hypertension, and left ventricular non-compaction cardiomyopathy
Population baseline characteristics and CMR parameters in the clinical setting
| Parameters | Median (interquartile range) or n (%) |
|---|---|
| Clinical | Overall (n = 100) |
| Gender, male | 41 (41%) |
| Age, years | 61 (53–69) |
| Body mass index, kg/m2 | 28 (24–32) |
| Body surface area, m2 | 1.9 (1.8–2.1) |
| Race, % | |
| Black | 42 (42%) |
| White | 44 (44%) |
| Hispanic | 7 (7%) |
| Asian | 5 (5%) |
| Unknown | 2 (2%) |
| Diagnosis, n (%) | |
| Coronary artery disease | 56 (56%) |
| Hypertension | 81 (81%) |
| Diabetes | 42 (42%) |
| Post-heart transplant | 5 (5%) |
| Post-CABG | 19 (19%) |
| Congenital heart disease | 2 (2%) |
| Pulmonary hypertension | 7 (7%) |
| Chronic lung disease | 25 (25%) |
| Obstructive sleep apnea | 14 (14%) |
| Cardiomyopathy | 39 (39%) |
| ICM | 16 (16%) |
| NICM | 23 (23%) |
| CMR | |
| LVEDV, ml | 157 (123–205) |
| LVEDVI, ml/m2 | 80 (67–105) |
| LVESV, ml | 80 (52–125) |
| LVESVI, ml/m2 | 40 (27–63) |
| LVM, g | 110 (88–129) |
| LVMI, g/m2 | 56 (46–66) |
| LVEF, % | 49 (39–61) |
| RVEDV, ml | 149 (116–173) |
| RVEDVI, ml/m2 | 75 (62–89) |
| RVESV, ml | 69 (50–95) |
| RVESVI, ml/m2 | 35 (26–49) |
| RVEF, % | 54 (45–58) |
| LGE, n (%) | 43 (43%) |
| Ischemic pattern | 29 (29%) |
| Non-ischemic pattern | 10 (10%) |
| Both patterns | 4 (4%) |
ICM ischemic cardiomyopathy, LGE late gadolinium enhancement, LVEDV left ventricular end-diastolic volume, LVEDVI left ventricular end-diastolic volume index, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, LVESVI left ventricular end-systolic volume index, LVM left ventricular mass, LVMI left ventricular mass index, NICM non-ischemic cardiomyopathy, RVEDV right ventricular end-diastolic volume, RVEDVI right ventricular end-diastolic volume index, RVEF right ventricular ejection fraction, RVESV right ventricular end-systolic volume, RVESVI right ventricular end-systolic volume index
Fig. 1Examples of images of contours detected by the core lab (CORE), original deep learning (DL1) and updated deep learning (DL2) (shown from top to bottom). Non-ischemic cardiomyopathy at basal slice
Fig. 2Linear regression plots (top) and Bland–Altman plots (bottom) comparing CORE and DL1 (left), CORE and DL2 (right). Red lines represent the regression lines, and green lines represent perfect agreement (unity lines)
Fig. 3Histograms showing the distribution of absolute differences between CORE right ventricular ejection fraction (RVEF) versus DL1 RVEF (left) and CORE RVEF versus DL2 RVEF (right) for Group 1 (top) and Group 2 (bottom). See text for details
Fig. 4Linear regression plots (left) comparing CORE RVEDV and DL1 RVEDV (A), CORE RVEDV and DL2 RVEDV (B), CORE RVESV and DL1 RVESV (E), CORE RVESV and DL2 RVESV (F). Bland–Altman plots (right) comparing CORE RVEDV and DL1 RVEDV (C), CORE RVEDV and DL2 RVEDV (D), CORE RVESV and DL1 RVESV (G), CORE RVESV and DL2 RVESV (H). Red lines represent the regression lines, and green lines represent perfect agreement (unity lines). RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume
Population characteristics and imaging parameters in subgroups
| Parameters | Median (interquartile range) or n (%) | ||
|---|---|---|---|
| Clinical | RVEF ≤ 35% (n = 11) | RVEF35-50% (n = 21) | RVEF ≥ 50% (n = 68) |
| Gender, male | 6 (55%) | 15 (71%) | 38 (56%) |
| Age, years | 59 (51–80) | 63 (50–69) | 61 (54–69) |
| Body mass index, kg/m2 | 29 (25–38) | 26 (23–31) | 29(25–32) |
| Body surface area, m2 | 2.0 (1.8–2.4) | 1.9 (1.7–2.2) | 2.0 (1.8–2.1) |
| Race, % | |||
| Black | 8 (73%) | 9 (43%) | 25 (37%) |
| White | 2 (18%) | 11 (52%) | 31 (46%) |
| Hispanic | 1 (9%) | 0 (0) | 6 (9%) |
| Asian | 0 (0) | 0 (0) | 5 (7%) |
| Unknown | 0 (0) | 1 (5%) | 1 (2%) |
| Diagnosis, n (%) | |||
| Coronary artery disease | 4 (36%) | 10 (48%) | 42 (62%) |
| Hypertension | 8 (73%) | 17 (81%) | 56 (82%) |
| Diabetes | 6 (55%) | 7 (33%) | 29 (43%) |
| Post-heart transplant | 0 (0) | 1 (5%) | 4 (6%) |
| Post-CABG | 2 (18%) | 2 (10%) | 15 (22%) |
| Congenital heart disease | 0 (0) | 0 (0) | 2 (3%) |
| Pulmonary hypertension | 1 (9%) | 3 (14%) | 3 (4%) |
| Chronic lung disease | 0(0)● | 11 (52%)# | 14 (21%) |
| OSA | 1 (9%) | 1(5%) | 12 (18%) |
| Cardiomyopathy | 10 (91%)* | 12 (57%)# | 17 (25%) |
| ICM | 4 (36%)* | 4 (19%) | 8 (12%) |
| NICM | 6 (55%)* | 8 (38%)# | 9 (13%) |
| CMR | |||
| LVEDV, ml | 238 (179–310)* | 166 (136–218) | 147 (116–192) |
| LV DVI, ml/m2 | 124 (85–139)* | 97 (74–124)# | 71 (64–97) |
| LVESV, ml | 176 (128–234)●* | 111 (72–134)# | 65 (47–100) |
| LVESVI, ml/m2 | 93 (62–105)●* | 55 (38–75) # | 32 (24–52) |
| LVM, g | 115 (103–226) * | 125 (107–140)# | 101 (83–122) |
| LVMI, g/m2 | 62 (54–93)* | 66 (54–76)# | 52 (44–61) |
| LVEF, % | 27 (22–30)●* | 43 (36–47)# | 54 (44–63) |
| RVEDV, ml | 190 (148–224)* | 164 (124–191) | 134 (113–164) |
| RVEDVI, ml/m2 | 87 (74–115)* | 85 (74–95)# | 71 (61–81) |
| RVESV, ml | 131 (108–161)* | 95 (75–112)# | 59 (46–73) |
| RESVI, ml/m2 | 65 (54–77)●* | 50 (42–54)# | 30 (25–36) |
| RV EF, % | 27 (26–32)●* | 43 (40–46)# | 58 (53–61) |
| LGE, n (%) | 8 (73%)●* | 9(43%) | 26 (38%) |
| Ischemic pattern | 1 (9%)●* | 6 (29%) | 22 (32%) |
| Non-ischemic pattern | 5 (46%)* | 2 (10%) | 3 (4%) |
| Both patterns | 2 (18%) | 1 (5%) | 1 (2%) |
ICM ischemic cardiomyopathy, LGE late gadolinium enhancement, LVEDV left ventricular end-diastolic volume, LVEDVI left ventricular end-diastolic volume index, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, LVESVI left ventricular end-systolic volume index, LVM left ventricular mass, LVMI left ventricular mass index, NICM non-ischemic cardiomyopathy, RVEDV right ventricular end-diastolic volume, RVEDVI right ventricular end-diastolic volume index, RVEF right ventricular ejection fraction, RVESV right ventricular end-systolic volume, RVESVI right ventricular end-systolic volume index
●P < 0.05, RVEF ≤ 35% and RVEF 35–50%
*P < 0.05, RVEF ≤ 35% and RVEF ≥ 50%
#P < 0.05, RVEF 35–50% and RVEF ≥ 50%
Fig. 5Confusion matrices showing accuracy of DL-RVEF to correctly categorize into clinically meaningful RVEF groups as defined by the RVEF by core lab (CORE-RVEF). Across true label rows, the numbers in the boxes represent the number and percentage of labels classified for each group. Color intensity corresponds to percentage, see heat map on the right
Fig. 6Example of images with contours detected by CORE, DL1 and DL2 algorithms. CORE and DL2 identified the correct ED and ES phases, but DL1 identified an incorrect ES phase. The CORE-RVEF was 52%, DL1-RVEF was 24%, and DL2-RVEF was 50%